Impact of novel glucose-lowering therapies on physical function in people with type 2 diabetes; a systematic review and meta-analysis of randomised placebo-controlled trials.

GLP-1RAs showed improvements in self-reported outcomes of physical function. However, there is limited evidence to draw definitive conclusions especially because of lack of studies exploring the impact of SGLT2i and DPP4i on physical function. There is a need for dedicated trials to establish the association between novel agents and physical function.